Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113635 | 0.88 | S1PR3 (0.52) | S1PR1S1PR3S1PR5NPC1RAB9A | |
| SCHEMBL28657010 | 0.86 | S1PR1 (0.55) | S1PR1S1PR3S1PR5 | |
| SCHEMBL4951756 | 0.84 | S1PR1 (0.55) | S1PR1S1PR3S1PR5 | |
| SCHEMBL28656867 | 0.84 | S1PR1 (0.62) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1969165 | 0.83 | S1PR1 (0.50) | S1PR1S1PR3S1PR5MAPT | |
| SCHEMBL12582041 | 0.82 | MAP4K4 (0.45) | S1PR1S1PR3MAPT | |
| SCHEMBL1969686 | 0.82 | MAP4K4 (0.60) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3456562 | 0.81 | ALDH1A3 (0.59) | S1PR1S1PR3S1PR5NPC1RAB9A | |
| SCHEMBL8283256 | 0.81 | S1PR1 (0.62) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1965122 | 0.80 | S1PR1 (0.62) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497255-B2 | Phosphonic acids as S1P receptor modulators | ALLERGAN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120129814-A1 | NOVEL PHOSPHONIC ACIDS AS S1P RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129814-A1 | NOVEL PHOSPHONIC ACIDS AS S1P RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885S1PR5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.